NIH #5P50CA070907-25
Project 2: Targeting Immune Vulnerabilities in Lung Cancer
Expiring Soon
- Amount
- $309K
- Period
- 1997-09-05 → 2026-08-31
- PIs
- 1
- Est. capacity / PI
- ~0 students
Awarded at UT SOUTHWESTERN MEDICAL CENTER
NIH #5R01CA287279-02
Deciphering the structural determinants of response and resistance to HER2-targeted antibody-drug conjugates and tyrosine kinase inhibitors for HER2-mutant Non-Small Cell Lung Cancer
Active
- Amount
- $679K
- Period
- 2025-04-01 → 2030-03-31
- PIs
- 2
- Est. capacity / PI
- ~4 students
Awarded at UNIVERSITY OF TX MD ANDERSON CAN CTR
NIH #1R01CA287279-01A1
Deciphering the structural determinants of response and resistance to HER2-targeted antibody-drug conjugates and tyrosine kinase inhibitors for HER2-mutant Non-Small Cell Lung Cancer
Active
- Amount
- $695K
- Period
- 2025-04-01 → 2030-03-31
- PIs
- 2
- Est. capacity / PI
- ~4 students
Awarded at UNIVERSITY OF TX MD ANDERSON CAN CTR
NIH #5P30CA016672-49
10 Lung Cancer
- Amount
- $25K
- Period
- 1996-08-28 → 2026-06-30
- PIs
- 1
- Est. capacity / PI
- ~0 students
Awarded at UNIVERSITY OF TX MD ANDERSON CAN CTR
NIH #4P30CA016672-48
10 Lung Cancer
- Amount
- $23K
- Period
- 1996-08-28 → 2026-06-30
- PIs
- 1
- Est. capacity / PI
- ~0 students
Awarded at UNIVERSITY OF TX MD ANDERSON CAN CTR
NIH #5U01CA256780-05
Molecular and immunological heterogeneity of Small Cell Lung Cancer (SCLC) and its impact on relapse and therapeutic response
- Amount
- $606K
- Period
- 2021-06-01 → 2026-05-31
- PIs
- 3
- Est. capacity / PI
- ~0 students
Awarded at UNIVERSITY OF TX MD ANDERSON CAN CTR
NIH #5U01CA256780-04
Molecular and immunological heterogeneity of Small Cell Lung Cancer (SCLC) and its impact on relapse and therapeutic response
- Amount
- $575K
- Period
- 2021-06-01 → 2026-05-31
- PIs
- 3
- Est. capacity / PI
- ~0 students
Awarded at UNIVERSITY OF TX MD ANDERSON CAN CTR
NIH #5U01CA256780-03
Molecular and immunological heterogeneity of Small Cell Lung Cancer (SCLC) and its impact on relapse and therapeutic response
- Amount
- $562K
- Period
- 2021-06-01 → 2026-05-31
- PIs
- 3
- Est. capacity / PI
- ~0 students
Awarded at UNIVERSITY OF TX MD ANDERSON CAN CTR
NIH #5U01CA256780-02
Molecular and immunological heterogeneity of Small Cell Lung Cancer (SCLC) and its impact on relapse and therapeutic response
- Amount
- $593K
- Period
- 2021-06-01 → 2026-05-31
- PIs
- 3
- Est. capacity / PI
- ~0 students
Awarded at UNIVERSITY OF TX MD ANDERSON CAN CTR
NIH #1U01CA256780-01
Molecular and immunological heterogeneity of Small Cell Lung Cancer (SCLC) and its impact on relapse and therapeutic response
- Amount
- $621K
- Period
- 2021-06-01 → 2026-05-31
- PIs
- 3
- Est. capacity / PI
- ~0 students
Awarded at UNIVERSITY OF TX MD ANDERSON CAN CTR
NIH #5R01CA247975-05
Molecular features impacting drug resistance in atypical EGFR exon 18 and exon 20 mutant non-small cell lung cancers and the development of novel mutant-selective inhibitors
- Amount
- $549K
- Period
- 2020-04-01 → 2025-09-30
- PIs
- 2
- Est. capacity / PI
- ~0 students
Awarded at UNIVERSITY OF TX MD ANDERSON CAN CTR
NIH #5P50CA070907-24
Targeting Lung Cancer Vulnerabilities
- Amount
- $2.1M
- Period
- 1997-09-05 → 2025-08-31
- PIs
- 2
- Est. capacity / PI
- ~0 students
Awarded at UT SOUTHWESTERN MEDICAL CENTER
NIH #5P50CA070907-23
Targeting Lung Cancer Vulnerabilities
- Amount
- $2.1M
- Period
- 1997-09-05 → 2025-08-31
- PIs
- 2
- Est. capacity / PI
- ~0 students
Awarded at UT SOUTHWESTERN MEDICAL CENTER
NIH #5P50CA070907-22
Targeting Lung Cancer Vulnerabilities
- Amount
- $2.1M
- Period
- 1997-09-05 → 2025-08-31
- PIs
- 3
- Est. capacity / PI
- ~0 students
Awarded at UT SOUTHWESTERN MEDICAL CENTER
NIH #5R01CA247975-04
Molecular features impacting drug resistance in atypical EGFR exon 18 and exon 20 mutant non-small cell lung cancers and the development of novel mutant-selective inhibitors
- Amount
- $567K
- Period
- 2020-04-01 → 2025-03-31
- PIs
- 2
- Est. capacity / PI
- ~0 students
Awarded at UNIVERSITY OF TX MD ANDERSON CAN CTR
NIH #5R01CA247975-03
Molecular features impacting drug resistance in atypical EGFR exon 18 and exon 20 mutant non-small cell lung cancers and the development of novel mutant-selective inhibitors
- Amount
- $567K
- Period
- 2020-04-01 → 2025-03-31
- PIs
- 2
- Est. capacity / PI
- ~0 students
Awarded at UNIVERSITY OF TX MD ANDERSON CAN CTR
NIH #5R01CA247975-02
Molecular features impacting drug resistance in atypical EGFR exon 18 and exon 20 mutant non-small cell lung cancers and the development of novel mutant-selective inhibitors
- Amount
- $578K
- Period
- 2020-04-01 → 2025-03-31
- PIs
- 2
- Est. capacity / PI
- ~0 students
Awarded at UNIVERSITY OF TX MD ANDERSON CAN CTR
NIH #1R01CA247975-01
Molecular features impacting drug resistance in atypical EGFR exon 18 and exon 20 mutant non-small cell lung cancers and the development of novel mutant-selective inhibitors
- Amount
- $578K
- Period
- 2020-04-01 → 2025-03-31
- PIs
- 2
- Est. capacity / PI
- ~0 students
Awarded at UNIVERSITY OF TX MD ANDERSON CAN CTR
NIH #5R01CA234183-05
Therapeutic strategies against EGFR exon 20 mutant lung cancer
- Amount
- $530K
- Period
- 2019-12-01 → 2024-11-30
- PIs
- 2
- Est. capacity / PI
- ~0 students
Awarded at UNIVERSITY OF TX MD ANDERSON CAN CTR
NIH #5R01CA234183-04
Therapeutic strategies against EGFR exon 20 mutant lung cancer
- Amount
- $546K
- Period
- 2019-12-01 → 2024-11-30
- PIs
- 2
- Est. capacity / PI
- ~0 students
Awarded at UNIVERSITY OF TX MD ANDERSON CAN CTR
NIH #5R01CA234183-03
Therapeutic strategies against EGFR exon 20 mutant lung cancer
- Amount
- $546K
- Period
- 2019-12-01 → 2024-11-30
- PIs
- 2
- Est. capacity / PI
- ~0 students
Awarded at UNIVERSITY OF TX MD ANDERSON CAN CTR
NIH #5R01CA234183-02
Therapeutic strategies against EGFR exon 20 mutant lung cancer
- Amount
- $557K
- Period
- 2019-12-01 → 2024-11-30
- PIs
- 2
- Est. capacity / PI
- ~0 students
Awarded at UNIVERSITY OF TX MD ANDERSON CAN CTR
NIH #1R01CA234183-01A1
Therapeutic strategies against EGFR exon 20 mutant lung cancer
- Amount
- $573K
- Period
- 2019-12-01 → 2024-11-30
- PIs
- 2
- Est. capacity / PI
- ~0 students
Awarded at UNIVERSITY OF TX MD ANDERSON CAN CTR
NIH #3P50CA070907-23S1
Targeting Lung Cancer Vulnerabilities
- Amount
- $46K
- Period
- 2023-05-01 → 2024-08-31
- PIs
- 2
- Est. capacity / PI
- ~0 students
Awarded at UT SOUTHWESTERN MEDICAL CENTER
NIH #5P30CA016672-47
10 Lung Cancer
- Amount
- $19K
- Period
- 1996-08-28 → 2024-06-30
- PIs
- 1
- Est. capacity / PI
- ~0 students
Awarded at UNIVERSITY OF TX MD ANDERSON CAN CTR
NIH #5P30CA016672-46
10 Lung Cancer
- Amount
- $19K
- Period
- 1996-08-28 → 2024-06-30
- PIs
- 1
- Est. capacity / PI
- ~0 students
Awarded at UNIVERSITY OF TX MD ANDERSON CAN CTR
NIH #5P30CA016672-45
10 Lung Cancer
- Amount
- $19K
- Period
- 1996-08-28 → 2024-06-30
- PIs
- 1
- Est. capacity / PI
- ~0 students
Awarded at UNIVERSITY OF TX MD ANDERSON CAN CTR
NIH #3P50CA070907-24S1
Targeting Lung Cancer Vulnerabilities
- Amount
- $118K
- Period
- 1997-09-05 → 2024-01-01
- PIs
- 2
- Est. capacity / PI
- ~0 students
Awarded at UT SOUTHWESTERN MEDICAL CENTER
NIH #5U01CA213273-05
Novel therapeutic approaches for enhancing anti-tumor immunity in SCLC
- Amount
- $551K
- Period
- 2017-08-01 → 2022-07-31
- PIs
- 3
- Est. capacity / PI
- ~0 students
Awarded at UNIVERSITY OF TX MD ANDERSON CAN CTR
NIH #5U01CA213273-04
Novel therapeutic approaches for enhancing anti-tumor immunity in SCLC
- Amount
- $703K
- Period
- 2017-08-01 → 2022-07-31
- PIs
- 3
- Est. capacity / PI
- ~0 students
Awarded at UNIVERSITY OF TX MD ANDERSON CAN CTR
NIH #5U01CA213273-03
Novel therapeutic approaches for enhancing anti-tumor immunity in SCLC
- Amount
- $574K
- Period
- 2017-08-01 → 2022-07-31
- PIs
- 3
- Est. capacity / PI
- ~0 students
Awarded at UNIVERSITY OF TX MD ANDERSON CAN CTR
NIH #5U01CA213273-02
Novel therapeutic approaches for enhancing anti-tumor immunity in SCLC
- Amount
- $596K
- Period
- 2017-08-01 → 2022-07-31
- PIs
- 3
- Est. capacity / PI
- ~0 students
Awarded at UNIVERSITY OF TX MD ANDERSON CAN CTR
NIH #1U01CA213273-01A1
Novel therapeutic approaches for enhancing anti-tumor immunity in SCLC
- Amount
- $615K
- Period
- 2017-08-01 → 2022-07-31
- PIs
- 3
- Est. capacity / PI
- ~0 students
Awarded at UNIVERSITY OF TX MD ANDERSON CAN CTR
NIH #5R01CA190628-05
Overcoming Resistance to Anti-EGFR Therapy by Drug Repurposing
- Amount
- $499K
- Period
- 2015-08-01 → 2021-07-31
- PIs
- 2
- Est. capacity / PI
- ~0 students
Awarded at UNIVERSITY OF TX MD ANDERSON CAN CTR
NIH #5R01CA205150-05
Therapeutic approaches for LKB1-deficient non-small cell lung cancer
- Amount
- $605K
- Period
- 2016-04-01 → 2021-03-31
- PIs
- 2
- Est. capacity / PI
- ~0 students
Awarded at UNIVERSITY OF TX MD ANDERSON CAN CTR
NIH #5R01CA205150-04
Therapeutic approaches for LKB1-deficient non-small cell lung cancer
- Amount
- $587K
- Period
- 2016-04-01 → 2021-03-31
- PIs
- 2
- Est. capacity / PI
- ~0 students
Awarded at UNIVERSITY OF TX MD ANDERSON CAN CTR
NIH #5R01CA205150-03
Therapeutic approaches for LKB1-deficient non-small cell lung cancer
- Amount
- $605K
- Period
- 2016-04-01 → 2021-03-31
- PIs
- 2
- Est. capacity / PI
- ~0 students
Awarded at UNIVERSITY OF TX MD ANDERSON CAN CTR
NIH #5R01CA205150-02
Therapeutic approaches for LKB1-deficient non-small cell lung cancer
- Amount
- $605K
- Period
- 2016-04-01 → 2021-03-31
- PIs
- 2
- Est. capacity / PI
- ~0 students
Awarded at UNIVERSITY OF TX MD ANDERSON CAN CTR
NIH #5R01CA190628-04
Overcoming Resistance to Anti-EGFR Therapy by Drug Repurposing
- Amount
- $514K
- Period
- 2015-08-01 → 2020-07-31
- PIs
- 2
- Est. capacity / PI
- ~0 students
Awarded at UNIVERSITY OF TX MD ANDERSON CAN CTR
NIH #5P30CA016672-44
10 Lung Cancer
- Amount
- $19K
- Period
- — → —
- PIs
- 1
- Est. capacity / PI
- ~0 students
Awarded at UNIVERSITY OF TX MD ANDERSON CAN CTR
NIH #2P50CA070907-21A1
Project 2: Targeting Immune Vulnerabilities in Lung Cancer
- Amount
- $304K
- Period
- — → —
- PIs
- 1
- Est. capacity / PI
- ~5 students
Awarded at UT SOUTHWESTERN MEDICAL CENTER
NIH #3P30CA016672-43S1
10 Lung Cancer
- Amount
- $5K
- Period
- — → —
- PIs
- 1
- Est. capacity / PI
- ~0 students
Awarded at UNIVERSITY OF TX MD ANDERSON CAN CTR
NIH #2P30CA016672-43
10 Lung Cancer
- Amount
- $19K
- Period
- — → —
- PIs
- 1
- Est. capacity / PI
- ~0 students
Awarded at UNIVERSITY OF TX MD ANDERSON CAN CTR